From the Journals

In utero exposure to valproate and other AEDs linked to low test scores

View on the News

Health informatics provide insights on AED risk during pregnancy

Performing a matched-case control study that links health records and national educational data is an innovative approach to assessing educational achievement in children born to mothers with epilepsy, according to Richard F.M. Chin, MD.

Lacey and colleagues demonstrated that in utero exposure to sodium valproate alone or antiepileptic drugs in combination was associated with significant decreases in educational achievement in national educational tests given to 7-year-old children, Dr Chin wrote in an editorial.

That finding may not seem new, given that multiple previous studies have linked in utero antiepileptic exposure to lower IQ, more frequent behavioral issues, and higher risk of psychiatric disorders. However, previous studies depended on detailed, resource-intensive, one-on-one assessments, or parent responses to questionnaires with potentially biased responses, Dr. Chin said. In contrast, Lacey and colleagues incorporating validated epilepsy diagnoses and made use of already available educational attainment data from the epilepsy cases and matched controls.

Because of that, their results may be more likely than previous studies to be representative of the general population, according to Dr. Chin.

“Such a relatively cost-effective and efficient approach has vast potential to be applicable for a number of other conditions and is at the heart of the emerging health informatics revolution,” he wrote.

Richard F.M. Chin is with the Muir Maxwell Epilepsy Centre, University of Edinburgh, Scotland. These comments are derived from his editorial published in the Journal of Neurology, Neurosurgery & Psychiatry (2018 Mar 25. doi: 10.1136/jnnp-2017-317924 ). Dr. Chin declared no competing interests related to the editorial.


 

FROM THE JOURNAL OF NEUROLOGY, NEUROSURGERY & PSYCHIATRY

In the United Kingdom, already-stringent guidance on valproate in pregnancy was strengthened on March 23 when the European Medicines Agency announced new measures designed to avoid valproate exposure in pregnancy because of risk of malformations and developmental issues. The measures include a ban on valproate-containing medicines for the treatment of epilepsy during pregnancy unless no other effective treatment is available.

The risks of AEDs, and valproate in particular, in pregnancy have been documented in multiple studies suggesting that exposure may lead to cognitive impairment, neurodevelopmental disorders, and impaired IQ. However, the available data are largely from psychometric studies, Dr. Lacey and colleagues noted in their report. “It is important to know whether the psychometric differences demonstrated in research conditions translate to children in the community,” they wrote.

To address this, Dr. Lacey and coinvestigators conducted a study of standardized academic test results in children in Wales born to mothers with epilepsy who had been prescribed AEDs during pregnancy. They reviewed health records and identified 440 AED-exposed children who had available results for Key Stage 1 tests for mathematics, language, and science at the age of 7 years.

Among children whose mothers had been prescribed valproate during pregnancy, the proportion achieving U.K. minimum standards for all subjects was 12.7% lower than a matched control group, investigators said.

Next Article: